AU2019299213A1 - Cannabidiol combination compositions - Google Patents

Cannabidiol combination compositions Download PDF

Info

Publication number
AU2019299213A1
AU2019299213A1 AU2019299213A AU2019299213A AU2019299213A1 AU 2019299213 A1 AU2019299213 A1 AU 2019299213A1 AU 2019299213 A AU2019299213 A AU 2019299213A AU 2019299213 A AU2019299213 A AU 2019299213A AU 2019299213 A1 AU2019299213 A1 AU 2019299213A1
Authority
AU
Australia
Prior art keywords
glucosamine
cbd
composition
gln
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019299213A
Other languages
English (en)
Inventor
Tami Bar
Golan VAKNIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Companion Sciences LLC
Original Assignee
Companion Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Companion Sciences LLC filed Critical Companion Sciences LLC
Publication of AU2019299213A1 publication Critical patent/AU2019299213A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2019299213A 2018-07-02 2019-07-01 Cannabidiol combination compositions Abandoned AU2019299213A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692865P 2018-07-02 2018-07-02
US62/692,865 2018-07-02
PCT/US2019/040043 WO2020009950A1 (en) 2018-07-02 2019-07-01 Cannabidiol combination compositions

Publications (1)

Publication Number Publication Date
AU2019299213A1 true AU2019299213A1 (en) 2021-02-11

Family

ID=69060564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019299213A Abandoned AU2019299213A1 (en) 2018-07-02 2019-07-01 Cannabidiol combination compositions

Country Status (8)

Country Link
US (1) US20210275556A1 (https=)
EP (1) EP3817750A4 (https=)
JP (1) JP2021532171A (https=)
CN (1) CN112930183A (https=)
AU (1) AU2019299213A1 (https=)
BR (1) BR112020027097A2 (https=)
CA (1) CA3105082A1 (https=)
WO (1) WO2020009950A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017023A2 (pt) 2018-02-23 2021-03-02 Nicola Michael Spirtos terapêutica à base de cannabis e método de uso
IT201900016709A1 (it) * 2019-09-19 2021-03-19 Aqma Italia S P A Composizione antidolorifica e antinfiammatoria ad uso locale
US20210212950A1 (en) * 2020-01-15 2021-07-15 Resurgent Pharmaceuticals, Inc. Orally deliverable formulation to prevent all cause mortality and cardiovascular events
US11364255B2 (en) * 2020-07-01 2022-06-21 Karallief, Inc. Therapeutic herbal compositions for improving joint health
BR102020023664A2 (pt) * 2020-07-02 2022-01-11 Yuzu Llc Composições compreendendo canabidiol e flavononas
EP4182026A4 (en) * 2020-07-17 2024-10-02 India Globalization Capital, Inc. COMPOSITION BASED ON CANNABIDIOL (CBD) AND METHOD FOR TREATING PAIN

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887497B2 (en) * 2002-12-19 2005-05-03 Vitacost.Com, Inc. Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
AU2006249771A1 (en) * 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
JP5204578B2 (ja) * 2007-07-31 2013-06-05 全薬工業株式会社 関節痛改善用組成物、関節痛改善剤、あるいは食品
PL2444081T3 (pl) * 2010-10-19 2015-09-30 Parenteral A S Kompozycja do leczenia chorób zapalnych, zawierająca kwas bosweliowy i kannabidiol
SG10201402819WA (en) * 2014-06-02 2016-01-28 Beauty Nation Pte Ltd Composition for prevention and treatment of joint pain and the method of preparation thereof
US9486476B2 (en) * 2014-08-05 2016-11-08 Natures Products, Inc Fast acting joint relief formulations
US10398776B1 (en) * 2014-11-03 2019-09-03 Essential Green Goodness LLC Phonophoretic cannabidiol composition and transdermal delivery system
AU2016215094B2 (en) * 2015-02-05 2019-09-26 Colorado Can Llc Purified CBD and CBDA, and methods, compositions and products employing CBD or CBDA
US10542770B2 (en) * 2016-03-18 2020-01-28 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same
CA3025208A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
US10945967B2 (en) * 2017-05-30 2021-03-16 Jae Wang. Song Formulations of a transdermal patch for pain management
US20190000794A1 (en) * 2017-12-27 2019-01-03 Daniel S. Tanaka Transmucosal cannabinoid formulation including a chitosan excipeint
CN112969452A (zh) * 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
CN110575432B (zh) * 2018-06-08 2021-10-12 汉义生物科技（北京）有限公司 一种含有大麻二酚的组合物及其在动物用品中的应用
WO2020021545A1 (en) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol and glucosamine for treating inflammatory joint diseases

Also Published As

Publication number Publication date
EP3817750A4 (en) 2022-05-04
WO2020009950A1 (en) 2020-01-09
CN112930183A (zh) 2021-06-08
BR112020027097A2 (pt) 2021-03-30
CA3105082A1 (en) 2020-01-09
JP2021532171A (ja) 2021-11-25
US20210275556A1 (en) 2021-09-09
EP3817750A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
AU2019299213A1 (en) Cannabidiol combination compositions
TW202132248A (zh) 大麻二酚型大麻素化合物
JP2022546928A (ja) カンナビジオールを含む局所製剤、組成物の調製方法およびその使用
JP7322094B2 (ja) 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤
JP2020534362A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
CN107530317A (zh) 大麻素类和n‑酰基乙醇胺的组合
KR102350519B1 (ko) 말초성 염증 및 통증을 감소시키는데 유용한 울금 및 에키네시아 안구스티폴리아의 추출물을 함유하는 조성물
US11523998B2 (en) Anti-inflammatory formulations and uses thereof including a combination of palmitoylethanolamide and plant-based polyphenols
JP2004516257A (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
US20190151390A1 (en) Perilla extract composition
AU2008203101A1 (en) Topical compositions comprising telmesteine for treating dermatological disorders
CN100522983C (zh) 梓醇及其同系物的医药用途
JPWO2017111069A1 (ja) 止痒剤
JP2023523275A (ja) 疼痛管理のためのカンナビクロメン製剤
JP2020011985A (ja) メントール、リナロール及び／又はイシリンを用いる脳外傷及び卒中からの非炎症性ニューロン傷害の処置又は予防
EP3962473A1 (en) Formulation for pain management
JP7257091B2 (ja) 認知症の治療及び予防薬
MXPA04004380A (es) Tratamiento y prevencion de parestesia que comprende co-terapia con derivados anticonvulsivos y potasio.
US11759439B2 (en) Bromhexine for the treatment of pain
TW202406540A (zh) 類黃酮化合物在對抗蛇毒誘發的毒性上的用途
WO2005117592A1 (en) Treatment of dermatological conditions

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period